Lipoprotein and Apolipoproteins With Metabolic Liver Diseases

N/AUnknownNCT03220971

Chun-Hsiang Wang440 enrolled

Overview

Theranostic translation applications against viral, metabolic liver diseases and hepatic oncogenesis: lipoprotein and apolipoproteins at a crossroad

An intimate link between microbial infections, metabolic changes and oncogenesis has been drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease progression. Globally the burden of hepatitis B and C virus infections is 450 and 185 millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis, hepatocellular carcinoma and metabolic disorders

Study Type

OBSERVATIONAL

Enrollment

440

Conditions

Disorders of Lipoprotein Metabolism and Other Lipidaemias

Interventions

lipoprotein and apolipoproteinsOTHER

To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. above 20 years 2. nonalcoholic fatty liver disease 3. Non-Alcoholic Steatohepatitis Exclusion Criteria: 1\. alcohonic hepatitis 2. Autoimmune liver disease 3. HIV postive \-

Locations (1)

Chun-Hsiang Wang

Tainan, Taiwan

Outcomes

Primary Outcomes

Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad

Study the interplay between hepatitis C virus (HCV) and lipid metabolism(the HCV infection affects host lipid homeostasis, regarding transportation, synthesis, and catabolism.)

Time frame: 2years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.